Literature DB >> 9541172

Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts.

Y Takeda1, M Gotoh, K Dono, M Nishihara, T Grochowiecki, F Kimura, T Yoshida, Y Ohta, H Ota, H Ohzato, K Umeshita, T Takeda, N Matsuura, M Sakon, N Kayagaki, H Yagita, K Okumura, M Miyasaka, M Monden.   

Abstract

Fas ligand (FasL) is highly expressed in testicular tissues and thought to be responsible for protection from allograft rejection by inducing apoptosis of anti-graft activated T cells. FasL-expressing islets have been shown to induce a granulocyte-mediated inflammatory reaction. We investigated whether a graft can be protected from alloimmune responses by manipulating the Fas/FasL-system. We transplanted allogeneic islets under the kidney capsule of streptozotocin-induced diabetic mice together with testicular tissue. Significant prolongation of survival of C3H islet allograft was observed in C57BL/6 (B6) recipients transplanted with C3H testicular tissue, but not in those transplanted with C3H-gld testicular tissue expressing non-functional FasL. No significant prolongation was observed in B6-lpr recipients expressing non-functional Fas. Immunohistochemical staining of C3H testicular tissue in the composite graft showed a high expression of FasL, but not that of the C3H-gld testicular tissue. In situ terminal deoxynucleotidyl transferase-mediated dUDP-biotin catalysed DNA nick-end labelling (TUNEL) staining of a composite graft of C3H islet and testicular tissue in B6 recipients demonstrated extensive apoptosis of infiltrating mononuclear cells around the graft. The protective effect of C3H testicular tissue was abrogated when anti-FasL monoclonal antibody was administered i.p. postoperatively. Our results suggest that FasL-positive testicular allografts protect composite islet allografts and indicate that manipulation of Fas/FasL mediated apoptosis is a suitable strategy for controlling rejection of islet allografts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9541172     DOI: 10.1007/s001250050909

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

Review 1.  Challenges and emerging technologies in the immunoisolation of cells and tissues.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  Adv Drug Deliv Rev       Date:  2007-10-11       Impact factor: 15.470

2.  Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long-term graft-localized immune privilege.

Authors:  Kyle B Woodward; Hong Zhao; Pradeep Shrestha; Lalit Batra; Min Tan; Orlando Grimany-Nuno; Laura Bandura-Morgan; Nadir Askenasy; Haval Shirwan; Esma S Yolcu
Journal:  Am J Transplant       Date:  2020-01-05       Impact factor: 8.086

3.  Relative efficiency of porcine and human cytotoxic T-lymphocyte antigen 4 immunoglobulin in inhibiting human CD4+ T-cell responses co-stimulated by porcine and human B7 molecules.

Authors:  Tadatsura Koshika; Carol Phelps; Jason Fang; Seung Eun Lee; Minoru Fujita; David Ayares; David K C Cooper; Hidetaka Hara
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

4.  Comparison of therapeutic characteristics of islet cell transplantation simultaneous with pancreatic mesenchymal stem cell transplantation in rats with Type 1 diabetes mellitus.

Authors:  Ilknur Ozturk Unsal; Zeynep Ginis; Ferda Alparslan Pinarli; Aynur Albayrak; Erman Cakal; Mustafa Sahin; Tuncay Delibasi
Journal:  Stem Cell Rev Rep       Date:  2015-06       Impact factor: 5.739

Review 5.  Stromal cell-based immunotherapy in transplantation.

Authors:  Ronald Charles; Lina Lu; Shiguang Qian; John J Fung
Journal:  Immunotherapy       Date:  2011-12       Impact factor: 4.196

6.  Structural, cellular and molecular aspects of immune privilege in the testis.

Authors:  Nan Li; Tao Wang; Daishu Han
Journal:  Front Immunol       Date:  2012-06-11       Impact factor: 7.561

Review 7.  Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy?

Authors:  Sara Chiappalupi; Laura Salvadori; Giovanni Luca; Francesca Riuzzi; Riccardo Calafiore; Rosario Donato; Guglielmo Sorci
Journal:  Cell Prolif       Date:  2019-03-26       Impact factor: 6.831

8.  Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.

Authors:  A Houston; M W Bennett; G C O'Sullivan; F Shanahan; J O'Connell
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

9.  Local immunomodulation Fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance.

Authors:  Devon M Headen; Kyle B Woodward; María M Coronel; Pradeep Shrestha; Jessica D Weaver; Hong Zhao; Min Tan; Michael D Hunckler; William S Bowen; Christopher T Johnson; Lonnie Shea; Esma S Yolcu; Andrés J García; Haval Shirwan
Journal:  Nat Mater       Date:  2018-06-04       Impact factor: 43.841

Review 10.  Local Immunomodulatory Strategies to Prevent Allo-Rejection in Transplantation of Insulin-Producing Cells.

Authors:  Xi Wang; Natalie K Brown; Bo Wang; Kaavian Shariati; Kai Wang; Stephanie Fuchs; Juan M Melero-Martin; Minglin Ma
Journal:  Adv Sci (Weinh)       Date:  2021-07-14       Impact factor: 16.806

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.